http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer
-
Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
-
AskBio Partners with TPG and Vida Ventures
-
Zealand Pharma announces Emmanuel Dulac as new CEO
-
Biopharma in 2018: Vantage Releases Annual Analysis of Pharma, Biotech and Medtech Performance
-
Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors
-
Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update
-
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
-
Xenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEO
-
Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
-
Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update
-
Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update
-
Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston
-
PatientsLikeMe and Shire Pharmaceuticals Collaborate to Study Rare Genetic Diseases
-
Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update
-
Xenetic Biosciences to Present at the 29th Annual ROTH Conference
-
Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases
-
Xenetic Biosciences (XBIO) Receives $3 Million Milestone Payment from Shire (SHPG)
-
Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia
-
Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline
-
Multimedia Assets Available: Modern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease
-
Modern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease
-
Merrimack Pharma (MACK) Announces Final Phase 3 NAPOLI-1 Study Results; Previous OS Advantage Maintained
-
Final Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for the ONIVYDE® Regimen for Patients with Metastatic Pancreatic Cancer
-
Pharma companies gain competitive advantage from 1 day Masterclass on Artificial Intelligence in Pharma sales and marketing
-
Merrimack's (MACK) ONIVYDE Receives Positive CHMP Opinion
-
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union
-
Bioengineered Organ Implant Developer HART Names Accomplished Biotechnology Executive Dr. Blaine McKee to its Board
-
Epsilon Signs New Multi-Year Agreement To Provide Global Database Marketing Services For Worldwide Biotechnology Leader Shire
-
Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.
-
HighPoint Solutions and Veeva Systems Team Up to Deliver Industry-specific Master Data Management to Life Sciences Companies
-
Medtech Jobs Jump Thanks To Mergers, Biotech Has Most Efficient Employees
-
GenomeDx Announces Exclusive Marketing and Distribution Agreement for the Decipher Prostate Cancer Classifier in Israel and the Palestinian Authority
-
Shire Appoints Olivier Bohuon to its Board of Directors
-
OvaScience Expands Senior Team with Two New Key Hires
-
Druva Announces Fifth Consecutive Year of Impressive 100+ Percent Growth
-
Routes Europe Opens Amidst Global Open Skies Debate
-
Shire and Cincinnati Children's Establish Rare Disease Research Collaboration
-
Jeremy Bloom and Rand Fishkin to Keynote iPharma 2015: CBI's 14th Annual Marketing Innovation Summit

